Merck & Co. and Alectos Therapeutics have announced an Alzheimer’s disease collaboration to develop disease-modifying therapies that target the tau protein in its toxic hyperphosphorylated form. The deal, which represents Alectos’ first major partnership, is valued at US$298 M.